New painting joins MDA Art Collection
The Muscular Dystrophy Coordinating Committee brings together advocates and federal agencies with the goal of expanding, strengthening and coordinating MD research and care efforts
Update (Sept. 4, 2013): A videocast of the Aug. 26, 2013, MDCC meeting is now available. See Muscular Dystrophy Coordinating Committee (MDCC) Meeting — August 2013. Watch presentations by Valerie Cwik, MDA's executive vice president and chief medical and scientific officer, at time point 2:31:47; and Annie Kennedy, MDA's senior vice president for advocacy, at time point 4:11:26.
The conference provided opportunities for information-sharing and collaboration among scientific professionals from many disciplines
Turning neuromuscular disease research into treatments as quickly as possible was the overarching theme of dozens of formal presentations, nearly 200 scientific posters and countless informal conversations at the MDA Scientific Conference, April 21-24, 2013.
A palpable sense of excitement pervaded the sold-out event thanks to the unprecedented number of experimental treatments in clinical trials...
In my first six months in my new role, I’ve traveled the country meeting with MDA families, supporters, researchers, staff and others who care passionately about our mission. As a result, I’ve come to view the word HOPE in a new way. HOPE is not only the powerful intention to discover lifesaving treatments and cures. HOPE is a commodity that can be measured — in progress.
MDA partnered with a French muscle disease association to host a symposium on advancing gene therapy for neuromuscular diseases
Planning for the next generation of gene and stem cell therapies for muscular dystrophies — even as the first generation is still under development — was the theme of a joint symposium sponsored by MDA and the Association Française Contre les Myopathies (French Association Against Myopathies, or AFM) at the 16th annual meeting of the American Society of Gene & Cell Therapy (ASGCT).
Spring is a time of change and new growth, and MDA is experiencing a lot of both these days. No matter where you look, we’re innovating, extending our reach, leveraging our resources, supporting new initiatives and building partnerships.
MDA asks Sarepta Therapeutics' CEO Chris Garabedian about next steps for this promising new drug for DMD
MDA is pushing forward on all levels to accelerate the pace at which we’re able to translate scientific discoveries into improved health outcomes for individuals living with muscle disease.